The role of the glutamine transporter ASCT2 in antineoplastic therapy
AbstractCancer cells are metabolically reprogrammed to support their high rates of proliferation, continuous growth, survival, invasion, metastasis, and resistance to cancer treatments. Among changes in cancer cell bioenergetics, the role of glutamine metabolism has been receiving increasing attention. Increased glutaminolysis in cancer cells is associated with increased expression of membrane transporters that mediate the cellular uptake of glutamine. ASCT2 (Alanine, Serine, Cysteine Transporter 2) is a Na+-dependent transmembrane transporter overexpressed in cancer cells and considered to be the primary transporter for g...
Source: Cancer Chemotherapy and Pharmacology - January 19, 2021 Category: Cancer & Oncology Source Type: research

Correlations between serum cetuximab and EGFR-related markers, and skin disorders in head and neck cancer patients
ConclusionsHead and neck cancer patients with a higher serum IL-6 level tended to have a lower serum cetuximab level. Serum cetuximab had positive correlations to skin rash severity and its medication in the study population. (Source: Cancer Chemotherapy and Pharmacology)
Source: Cancer Chemotherapy and Pharmacology - January 19, 2021 Category: Cancer & Oncology Source Type: research

Phase II clinical trial of nab-paclitaxel plus gemcitabine in elderly patients with previously untreated locally advanced or metastatic pancreatic adenocarcinoma: the BIBABRAX study
ConclusionsOur study confirms the clinical benefit of the combination of nab-paclitaxel and gemcitabine in an elderly population with pancreatic cancer in terms of improved survival and clinical response. However, we were unable to confirm a benefit in terms of quality-of-life. (Source: Cancer Chemotherapy and Pharmacology)
Source: Cancer Chemotherapy and Pharmacology - January 15, 2021 Category: Cancer & Oncology Source Type: research

Does bevacizumab increase joint pain in patients with cancer? Results of the prospective observational BEVARTHRALGIA study
AbstractPurposeThe occurrence of arthralgia and myalgia during treatment with bevacizumab (Bev) has been described but not spontaneously reported. We aimed to evaluate the frequency of arthralgia in patients treated with Bev and identify the risk factors.MethodsIn this observational prospective study, a self-administered questionnaire was distributed to patients at the initiation of Bev and at 3 and 6  months of treatment. Bev (5–15 mg/kg) was administered every 2 or 3 weeks, with or without chemotherapy.ResultsA total of 71 patients (42 with colorectal cancer, 22 with ovarian cancer, and 7 with lung c...
Source: Cancer Chemotherapy and Pharmacology - January 12, 2021 Category: Cancer & Oncology Source Type: research

Disulfiram: a novel repurposed drug for cancer therapy
AbstractCancer is a major health issue worldwide and the global burden of cancer is expected to reduce the costs of treatment as well as prolong the survival time. One of the promising approaches is drug repurposing, because it reduces costs and shortens the production cycle of research and development. Disulfiram (DSF), which was originally approved as an anti-alcoholism drug, has been proven safe and shows the potential to target tumours. Its anti-tumour effect has been reported in many preclinical studies and recently on seven types of cancer in humans: non-small cell lung cancer (NSCLC), liver cancer, breast cancer, pr...
Source: Cancer Chemotherapy and Pharmacology - January 10, 2021 Category: Cancer & Oncology Source Type: research

A phase I study of intravenous fenretinide (4-HPR) for patients with malignant solid tumors
ConclusionFenretinide emulsion intravenous infusion had a manageable safety profile and achieved higher plasma steady-state concentrations of the active metabolite compared to previous capsule formulations. Single-agent activity was minimal but combinatorial approaches are under evaluation. (Source: Cancer Chemotherapy and Pharmacology)
Source: Cancer Chemotherapy and Pharmacology - January 10, 2021 Category: Cancer & Oncology Source Type: research

Tumor microenvironment promotes breast cancer chemoresistance
AbstractBreast cancer is presently the most predominant tumor type and the second leading cause of tumor-related deaths among women. Although advancements in diagnosis and therapeutics have momentously improved, chemoresistance remains an important challenge. Tumors oppose chemotherapeutic agents through a variety of mechanisms, with studies revealing that the tumor microenvironment (TME) is central to this process. The components of TME including stromal cells, immune cells, and non-stromal factors on exposure to chemotherapy promote the acquisition of resistant phenotype. Consequently, limited targeting of tumor cells le...
Source: Cancer Chemotherapy and Pharmacology - January 9, 2021 Category: Cancer & Oncology Source Type: research

Population pharmacokinetic model development and exposure –response analysis of vincristine in patients with malignant lymphoma
ConclusionThe population pharmacokinetics of VCR were evaluated in adult malignant lymphoma patients. VCR pharmacokinetic data could explain in part the adverse events and prognosis of these patients. (Source: Cancer Chemotherapy and Pharmacology)
Source: Cancer Chemotherapy and Pharmacology - January 8, 2021 Category: Cancer & Oncology Source Type: research

Concentration –QTc analysis of quizartinib in patients with relapsed/refractory acute myeloid leukemia
AbstractPurposeThis analysis evaluated the relationship between concentrations of quizartinib and its active metabolite AC886 and QT interval corrected using Fridericia ’s formula (QTcF) in patients with relapsed/refractory acute myeloid leukemia (AML) treated in the phase 3 QuANTUM-R study (NCT02039726).MethodsThe analysis dataset included 226 patients with AML. Quizartinib dihydrochloride was administered as daily doses of 20, 30, and 60  mg. Nonlinear mixed-effects modeling was performed using observed quizartinib and AC886 concentrations and time-matched mean electrocardiogram measurements.ResultsObserved QT...
Source: Cancer Chemotherapy and Pharmacology - January 8, 2021 Category: Cancer & Oncology Source Type: research

Demethoxycucumin protects MDA-MB-231 cells induced bone destruction through JNK and ERK pathways inhibition
In this study, we explored the effects of DMC on MDA-MB-231 cells, MCF-7 cells, and osteoclasts induced by RANKL in vitro, as well as the protective effect on bone destruction of tumor bone metastasis in vivo. DMC showed inhibitory effect on the migration and promotes the apoptosis of MDA-MB-231 and MCF-7 cells. At the same time, DMC inhibited osteoclast maturation and mature osteoclast bone resorption in a dose-dependent manner, and suppressed the expression of osteoclast marker genes TRAP, CTSK, MMP9, V-ATPase-d2 and DC-STAMP significantly. Biochemical data showed that DMC inhibited tumor cells and osteoclasts by inhibit...
Source: Cancer Chemotherapy and Pharmacology - January 5, 2021 Category: Cancer & Oncology Source Type: research

Enhancing the activity of platinum-based drugs by improved inhibitors of ERCC1 –XPF-mediated DNA repair
ConclusionOur results confirm the feasibility of the approach of targeting the protein –protein interaction between ERCC1 and XPF to sensitize cancer cells to alkylating agents, thanks to the improved binding affinity of the newly synthesized compounds. (Source: Cancer Chemotherapy and Pharmacology)
Source: Cancer Chemotherapy and Pharmacology - January 5, 2021 Category: Cancer & Oncology Source Type: research

Dose adjustment of venetoclax when co-administered with posaconazole: clinical drug –drug interaction predictions using a PBPK approach
ConclusionsThe posaconazole PBPK models were developed and clinically verified. Predictions using the robust PBPK model confirmed the venetoclax label recommendation of 70  mg in the presence of posaconazole at doses up to 500 mg QD. (Source: Cancer Chemotherapy and Pharmacology)
Source: Cancer Chemotherapy and Pharmacology - January 4, 2021 Category: Cancer & Oncology Source Type: research

Impact of interstitial lung disease associated with immune checkpoint inhibitors on prognosis in patients with non-small-cell lung cancer
ConclusionThe DAD pattern may predict short-term adverse prognosis for ICI-ILD. Once ICI-ILD is overcome, severity grade is not associated with prognosis. Even if initial immunotherapy proves effective, ICI rechallenge requires careful consideration. (Source: Cancer Chemotherapy and Pharmacology)
Source: Cancer Chemotherapy and Pharmacology - January 4, 2021 Category: Cancer & Oncology Source Type: research

Effect of ceritinib on the pharmacokinetics of coadministered CYP3A and 2C9 substrates: a phase I, multicenter, drug –drug interaction study in patients with ALK  + advanced tumors
ConclusionCeritinib is a strong CYP3A inhibitor and a weak CYP2C9 inhibitor. These findings should be reflected as actionable clinical recommendations in the prescribing information for ceritinib with regards to concomitant medications whose pharmacokinetics may be altered by ceritinib. (Source: Cancer Chemotherapy and Pharmacology)
Source: Cancer Chemotherapy and Pharmacology - January 4, 2021 Category: Cancer & Oncology Source Type: research

Evaluation of the impact of renal impairment on the pharmacokinetics of glasdegib in otherwise healthy volunteers
AbstractPurposeGlasdegib is being developed for indications in myeloid malignancies. The effect of renal impairment on the pharmacokinetics (PK) of a single, oral, 100-mg glasdegib dose under fasted conditions was assessed.MethodsOpen-label, parallel-group study (NCT03596567). Participants of good general health were selected and categorized, based on their estimated glomerular filtration rate, into normal ( ≥ 90 mL/min), moderate (≥ 30 to 
Source: Cancer Chemotherapy and Pharmacology - January 3, 2021 Category: Cancer & Oncology Source Type: research

The use of zebrafish model in prostate cancer therapeutic development and discovery
AbstractZebrafish is now among the leading in vivo model for cancer research, including prostate cancer. They are an alternative economic model being used to study cancer development, proliferation, and metastasis. They can also be effectively utilized for the development of cancer drugs at all levels, including target validation, and high-throughput screening for possible lead molecules. In this review, we provide a comprehensive overview of the role of zebrafish as an in vivo model in prostate cancer research. Globally, prostate cancer is a leading cause of death in men. Although many molecular mechanisms have been ident...
Source: Cancer Chemotherapy and Pharmacology - January 3, 2021 Category: Cancer & Oncology Source Type: research

FSTL1 increases cisplatin sensitivity in epithelial ovarian cancer cells by inhibition of NF- κB pathway
ConclusionFSTL1 may inhibit NF- κB signaling pathway to suppress the growth and promote the apoptosis of epithelial ovarian cancer cells, and thereby enhancing its DDP sensitivity. (Source: Cancer Chemotherapy and Pharmacology)
Source: Cancer Chemotherapy and Pharmacology - January 3, 2021 Category: Cancer & Oncology Source Type: research

Antitumor activity and mechanism of resistance of the novel HDAC and PI3K dual inhibitor CUDC-907 in pancreatic cancer
ConclusionTaken together, these findings support the clinical development of CUDC-907 for the treatment of pancreatic cancer and identify compensatory activation of mTOR and MEK/ERK as a possible mechanism of resistance to CUDC-907. (Source: Cancer Chemotherapy and Pharmacology)
Source: Cancer Chemotherapy and Pharmacology - January 3, 2021 Category: Cancer & Oncology Source Type: research

Pingyangmycin enhances the antitumor efficacy of anti-PD-1 therapy associated with tumor-infiltrating CD8 + T  cell augmentation
ConclusionsThe studies indicate that PYM, as an ICD inducer with mild myelosuppression effect, may enhance the therapeutic efficacy of anti-PD-1 antibody in association with tumor infiltrating CD8+ T cell augmentation. (Source: Cancer Chemotherapy and Pharmacology)
Source: Cancer Chemotherapy and Pharmacology - January 3, 2021 Category: Cancer & Oncology Source Type: research

Pegylated liposomal doxorubicin-induced renal toxicity in retroperitoneal liposarcoma: a case report and literature review
We describe the case of a 50-year-old man with advanced retroperitoneal liposarcoma who developed irreversible PLD-associated progr essive renal failure requiring chronic hemodialysis due to a thrombotic microangiopathy. No cardiotoxicity was noted 84 months after he initiated PLD. This case describes a lesser known toxicity of PLD and may be a toxicity of long-term treatment with other liposomal drugs. (Source: Cancer Chemotherapy and Pharmacology)
Source: Cancer Chemotherapy and Pharmacology - January 3, 2021 Category: Cancer & Oncology Source Type: research

FOLFIRINOX in advanced pancreatic cancer patients with the double-variant type of UGT1A1 *28 and *6 polymorphism: a multicenter, retrospective study
ConclusionBased on our findings, we recommend that in Japanese advanced PC patients with UGT1A1- DV treated with FOLFIRINOX, irinotecan be administered at an initial dose of  ≤ 120 mg/m2. (Source: Cancer Chemotherapy and Pharmacology)
Source: Cancer Chemotherapy and Pharmacology - January 2, 2021 Category: Cancer & Oncology Source Type: research

Population pharmacokinetic and pharmacodynamic modeling of capecitabine and its metabolites in breast cancer patients
ConclusionIn our study, we propose a model able to describe, meanwhile, and its main metabolites, with a complex absorption process and inclusion of enzyme activity covariates such as CDA and UH2/U ratio.Trial registration Eudract 2008-004136-20, 2008/11/26 (Source: Cancer Chemotherapy and Pharmacology)
Source: Cancer Chemotherapy and Pharmacology - January 2, 2021 Category: Cancer & Oncology Source Type: research

A phase 1 pharmacokinetic study of oral NEPA, the fixed combination of netupitant and palonosetron, in Chinese healthy volunteers
ConclusionFollowing single-dose administration of oral NEPA in Chinese subjects, the pharmacokinetic profiles of the NEPA components were mostly similar to those reported previously in Caucasians. NEPA was well tolerated with a safety profile in line with that observed in pivotal trials in Caucasians. (Source: Cancer Chemotherapy and Pharmacology)
Source: Cancer Chemotherapy and Pharmacology - January 2, 2021 Category: Cancer & Oncology Source Type: research

Correction to: Combination efficacy of pertuzumab and trastuzumab for trastuzumab emtansine-resistant cells exhibiting attenuated lysosomal trafficking or efflux pumps upregulation
In the original publication of the article, the author has found 2 errors as below. (Source: Cancer Chemotherapy and Pharmacology)
Source: Cancer Chemotherapy and Pharmacology - December 18, 2020 Category: Cancer & Oncology Source Type: research

Starting dose selection and dose escalation for oncology small molecule first-in-patient trials: learnings from a survey of FDA-approved drugs
AbstractThe ideal starting dose for an oncology first-in-patient (FIP) trial should be low enough to be safe but not too far removed from therapeutically relevant doses. A low starting dose combined with small dose increments could lead to a lengthy dose escalation and could expose patients unnecessarily to sub-therapeutic dosing. In the current analyses, we reviewed 59 approved small molecule oncology drugs (SMOD) with the overarching goals to assess the current approaches of FIP starting dose selection and dose escalation, and to identify potential opportunities for improving trial efficiency and minimizing number of pat...
Source: Cancer Chemotherapy and Pharmacology - November 25, 2020 Category: Cancer & Oncology Source Type: research

Overriding sorafenib resistance via blocking lipid metabolism and Ras by sphingomyelin synthase 1 inhibition in hepatocellular carcinoma
AbstractBackgroundThe survival benefit of sorafenib, the most used drug for advanced hepatocellular carcinoma (HCC), is unsatisfactory due to the development of adaptive resistance. Exploring the mechanisms underlying sorafenib resistance is important to develop sensitizing strategy. Sphingomyelin synthase (SMS) plays a critical role in sphingolipid metabolism which is involved in oncogenesis and drug resistance.MethodsSMS1 and SMS2 levels in HCC cells in response to prolonged chemotherapy were analyzed using ELISA. mRNA and protein levels of SMS in HCC and adjacent normal tissues were analyzed by ELISA and real-time PCR. ...
Source: Cancer Chemotherapy and Pharmacology - November 23, 2020 Category: Cancer & Oncology Source Type: research

PDK4 promotes tumorigenesis and cisplatin resistance in lung adenocarcinoma via transcriptional regulation of EPAS1
AbstractThe use of cisplatin for the treatment of non-small cell lung cancer has long been constrained by the rapid acquisition of tumor cell chemoresistance. In the present study, we sought to better elucidate the molecular mechanisms underlying this resistance phenotype. To that end, we assessed gene expression patterns in cisplatin-resistant lung adenocarcinoma cells, revealing pyruvate dehydrogenase lipoamide kinase isozyme 4 (PDK4) to be the most up-regulated kinase in resistant cells. We further found PDK4 upregulation to be directly linked with the acquisition of chemoresistance, driving enhanced tumor cell growth i...
Source: Cancer Chemotherapy and Pharmacology - November 21, 2020 Category: Cancer & Oncology Source Type: research

A Phase Ib multicenter, dose-escalation study of the polyamine analogue PG-11047 in combination with gemcitabine, docetaxel, bevacizumab, erlotinib, cisplatin, 5-fluorouracil, or sunitinib in patients with advanced solid tumors or lymphoma
ConclusionsResults of this Phase Ib trial indicate that PG-11047 can be safely administered to patients in combination with bevacizumab, erlotinib, cisplatin, and 5-FU on the once weekly dosing schedule described and may provide therapeutic benefit. The manageable toxicity profile and high MTD determination provide a safety profile for further clinical studies. (Source: Cancer Chemotherapy and Pharmacology)
Source: Cancer Chemotherapy and Pharmacology - November 19, 2020 Category: Cancer & Oncology Source Type: research

Correction to: Cyclooxygenase activity mediates colorectal cancer cell resistance to the omega ‑3 polyunsaturated fatty acid eicosapentaenoic acid
In the original publication of the article (Source: Cancer Chemotherapy and Pharmacology)
Source: Cancer Chemotherapy and Pharmacology - November 17, 2020 Category: Cancer & Oncology Source Type: research

Correction to: Successful management of hyperammonemia with hemodialysis on day 2 during 5 ‑fluorouracil treatment in a patient with gastric cancer: a case report with 5‑fluorouracil metabolite analyses
After publication in volume 86, issue 5, page 693 –699 the author decided to opt for Open Choice and to make the article an Open Access publication. (Source: Cancer Chemotherapy and Pharmacology)
Source: Cancer Chemotherapy and Pharmacology - November 12, 2020 Category: Cancer & Oncology Source Type: research

An investigation into possible interactions among four vascular epidermal growth factor receptor-tyrosine kinase inhibitors with gefitinib
The objective of present work is to evaluate possible interactions among four clinically-used vascular epidermal growth factor receptor (VEGFR)-tyrosine kinase inhibitors (TKIs), including apatinib, cabozantinib, sorafenib, and sunitinib, with epidermal growth factor receptor (EGFR)-TKI gefitinib. This may advance knowledge regarding possible dual-target suppression strategies for advanced NSCLC, including VEGFR-TKI plus EGFR-TKI. The in vitro metabolism study demonstrated that apatinib inhibited the formation of metabolite M537194 with moderate effect, and inhibited another metabolite formation of M523595 with strong effe...
Source: Cancer Chemotherapy and Pharmacology - November 10, 2020 Category: Cancer & Oncology Source Type: research

Effects of thymidylate synthase polymorphisms on toxicities associated with high-dose methotrexate in childhood acute lymphoblastic leukemia
ConclusionGenetic polymorphism ofTYMS1494del6 may modulate susceptibility to MTX toxicity. (Source: Cancer Chemotherapy and Pharmacology)
Source: Cancer Chemotherapy and Pharmacology - November 10, 2020 Category: Cancer & Oncology Source Type: research

Clinical utility of circulating tumor-associated cells to predict and monitor chemo-response in solid tumors
ConclusionTo our knowledge, this is the first expansive and in-depth study demonstrating that real-time CRP of C-TACs is a viable approach for non-invasive assessment of response to CCA in solid organ cancers. (Source: Cancer Chemotherapy and Pharmacology)
Source: Cancer Chemotherapy and Pharmacology - November 10, 2020 Category: Cancer & Oncology Source Type: research

Interactions between anti-EGFR therapies and cytotoxic chemotherapy in oesophageal squamous cell carcinoma: why clinical trials might have failed and how they could succeed
ConclusionGefitinib/platinum co-administration demonstrated antagonism suggesting a possible explanation for the lack of benefit from addition of anti-EGFR therapies to fluoropyrimidine/platinum chemotherapy in trials. Gefitinib/docetaxel co-administration demonstrated synergy suggesting taxanes could be the most effective cytotoxic partner for anti-EGFR therapies inEGFR CNG-positive ESCC, but careful consideration of drug scheduling is required. (Source: Cancer Chemotherapy and Pharmacology)
Source: Cancer Chemotherapy and Pharmacology - November 9, 2020 Category: Cancer & Oncology Source Type: research

A Phase 1 randomized study compare the pharmacokinetics, safety and immunogenicity of HLX02 to reference CN- and EU-sourced trastuzumab in healthy subjects
ConclusionThis study demonstrated comparable safety profiles and PK bioequivalence among HLX02, CN-trastuzumab and EU-trastuzumab in healthy Chinese male subjects.Clinical trial registrationClinicalTrials.gov, NCT02581748, registered at October 19, 2015. (Source: Cancer Chemotherapy and Pharmacology)
Source: Cancer Chemotherapy and Pharmacology - November 9, 2020 Category: Cancer & Oncology Source Type: research

Galeterone sensitizes breast cancer to chemotherapy via targeting MNK/eIF4E and β-catenin
AbstractAberrant activation of eIF4E signalling pathway is common in breast cancer and holds potential therapeutic options. In our work, galeterone as a chemical compound under clinical trials for the treatment of prostate cancer, was identified to be effective in targeting breast cancer cells via suppressing MNK-eIF4E and β-catenin. In despite of varying IC50, galeterone at nanomolar concentrations significantly decreased viability, proliferation and migration of a panel of breast cancer cell lines regardless of clinical subtypes and genetic mutations, and to a higher extent than in normal breast cells. Galetero...
Source: Cancer Chemotherapy and Pharmacology - November 7, 2020 Category: Cancer & Oncology Source Type: research

A phase I trial of temsirolimus and erlotinib in patients with refractory solid tumors
ConclusionThe combination of temsirolimus and erlotinib at the RP2D was well tolerated, and the regimen resulted in prolonged disease stabilization in selected patients (NCT00770263). (Source: Cancer Chemotherapy and Pharmacology)
Source: Cancer Chemotherapy and Pharmacology - November 6, 2020 Category: Cancer & Oncology Source Type: research

Exploring chemotherapy holiday and drugs re-challenge in advanced pancreatic cancer patients
ConclusionOur data endorse the strategy of resuming prior drugs after a chemotherapy holiday ≥ 3 months in advanced PDAC patients who achieved a  durable disease control after upfront treatments. (Source: Cancer Chemotherapy and Pharmacology)
Source: Cancer Chemotherapy and Pharmacology - November 6, 2020 Category: Cancer & Oncology Source Type: research

Dose exploration results from Phase 1 study of cemiplimab, a human monoclonal programmed death (PD)-1 antibody, in Japanese patients with advanced malignancies
ConclusionCemiplimab exhibited antitumor activity in Japanese patients with advanced malignancies. The safety profile was comparable to those previously reported for cemiplimab and other PD-1 inhibitors.Trial registrationNCT03233139 at ClinicalTrials.gov.Graphic abstract (Source: Cancer Chemotherapy and Pharmacology)
Source: Cancer Chemotherapy and Pharmacology - November 4, 2020 Category: Cancer & Oncology Source Type: research

Population pharmacokinetics of ATR inhibitor berzosertib in phase I studies for different cancer types
ConclusionsThere was no evidence of a clinically significant PK interaction between berzosertib and evaluated chemo-combinations. The covariate analysis did not highlight any need for dosing adjustments in the population studied to date.Clinical Trial informationNCT02157792, EudraCT 2013-005100-34 (Source: Cancer Chemotherapy and Pharmacology)
Source: Cancer Chemotherapy and Pharmacology - November 4, 2020 Category: Cancer & Oncology Source Type: research

HSD3B1 variant and androgen-deprivation therapy outcome in prostate cancer
ConclusionThe HSD3B1 (1245C) variant is a predictor of ADT plus CYP17A1 inhibitor response in prostate cancer. (Source: Cancer Chemotherapy and Pharmacology)
Source: Cancer Chemotherapy and Pharmacology - November 3, 2020 Category: Cancer & Oncology Source Type: research

MiniPDX-guided postoperative anticancer treatment can effectively prolong the survival of patients with hepatocellular carcinoma
ConclusionThe use of the MiniPDX model to select drugs to guide anti-tumor treatment after partial hepatectomy could effectively prolong the survival of patients with HCC. (Source: Cancer Chemotherapy and Pharmacology)
Source: Cancer Chemotherapy and Pharmacology - November 3, 2020 Category: Cancer & Oncology Source Type: research

Artemisinin-type drugs for the treatment of hematological malignancies
AbstractQinghaosu, known as artemisinin (ARS), has been for over two millennia, one of the most common herbs prescribed in traditional Chinese medicine (TCM). ARS was developed as an antimalarial drug and currently belongs to the established standard treatments of malaria as a combination therapy worldwide. In addition to the antimalarial bioactivity of ARS, anticancer activities have been shown both in vitro and in vivo. Like other natural products, ARS acts in a multi-specific manner also against hematological malignancies. The chemical structure of ARS is a sesquiterpene lactone, which contains an endoperoxide bridge es...
Source: Cancer Chemotherapy and Pharmacology - November 3, 2020 Category: Cancer & Oncology Source Type: research

Correction to: A placebo ‑controlled, double‑blind, randomized study of recombinant thrombomodulin (ART‑123) to prevent oxaliplatin‑induced peripheral neuropathy
In the Original publication of the article, the authors found an error in the “Results” section under the heading “Abstract”. The corrected text is given below. (Source: Cancer Chemotherapy and Pharmacology)
Source: Cancer Chemotherapy and Pharmacology - November 2, 2020 Category: Cancer & Oncology Source Type: research

Successful management of hyperammonemia with hemodialysis on day 2 during 5-fluorouracil treatment in a patient with gastric cancer: a case report with 5-fluorouracil metabolite analyses
We present a case of an advanced gastric cancer patient with chronic renal failure, who was treated with 5FU/leucovorin (LV) infusion chemotherapy (2-h infusion of LV and 5FU bolus followed by 46-h 5FU continuous infusion on day 1; repeated every 2  weeks) and developed hyperammonemia, with the aim of exploring an appropriate hemodialysis (HD) schedule to resolve its symptoms.MethodsThe blood concentrations of 5FU and its metabolites, α-fluoro-β-alanine (FBAL), and monofluoroacetate (FA) of a patient who had hyperammonemia from seven courses of palliative 5FU/LV therapy for gastric cancer were...
Source: Cancer Chemotherapy and Pharmacology - October 29, 2020 Category: Cancer & Oncology Source Type: research

Involvement of cytochrome P450 enzymes in inflammation and cancer: a review
AbstractCytochrome P450 (CYP) enzymes are responsible for the biotransformation of drugs, xenobiotics, and endogenous substances. This enzymatic activity can be modulated by intrinsic and extrinsic factors, modifying the organism ’s response to medications. Among the factors that are responsible for enzyme inhibition or induction is the release of proinflammatory cytokines, such as interleukin-1 (IL-1), IL-6, tumor necrosis factor α (TNF-α), and interferon-γ (IFN-γ), from macrophages, lymphocytes, and neutrophils. Thes e cells are also present in the tumor microenvironment, participating in th...
Source: Cancer Chemotherapy and Pharmacology - October 28, 2020 Category: Cancer & Oncology Source Type: research

Effect of lurbinectedin on the QTc interval in patients with advanced solid tumors: an exposure –response analysis
This study assessed the effect of lurbinectedin, a highly selective inhibitor of oncogenic transcription, on the change from baseline in Fridericia ’s corrected QT interval (∆QTcF) and electrocardiography (ECG) morphological patterns, and lurbinectedin concentration–∆QTcF (C-∆QTcF) relationship, in patients with advanced solid tumors.MethodsPatients with QTcF  ≤ 500 ms, QRS 
Source: Cancer Chemotherapy and Pharmacology - October 27, 2020 Category: Cancer & Oncology Source Type: research

Retraction Note to: Aplysin enhances temozolomide sensitivity in glioma cells by increasing miR ‑181 level
This article has been retracted. Please see the Retraction Notice for more detail: https://doi.org/10.1007/s0028 0-014-2534-5 (Source: Cancer Chemotherapy and Pharmacology)
Source: Cancer Chemotherapy and Pharmacology - October 26, 2020 Category: Cancer & Oncology Source Type: research

Analysis of pharmacogenomic factors for chemotherapy-induced nausea and vomiting in patients with breast cancer receiving doxorubicin and cyclophosphamide chemotherapy
ConclusionNo significant association was found betweenABCB1 2677G  >  T/A and CR0 –24. However, it was observed that the polymorphism ofTACR1, which encodes the neurokinin 1 receptor, might be a potential genetic risk factor for the development of delayed phase CINV. (Source: Cancer Chemotherapy and Pharmacology)
Source: Cancer Chemotherapy and Pharmacology - October 24, 2020 Category: Cancer & Oncology Source Type: research

Phase 1 study of Gemcitabine/Nab-paclitaxel/S-1 in patients with unresectable pancreatic cancer (GeNeS1S trial)
ConclusionWe defined the maximum tolerated dose and the recommended dose for combination therapy with gemcitabine/nab-paclitaxel/S-1 as dose level-1. Considering the observed response rate, further studies are warranted in order to determine the efficacy of this regimen (UMIN-CTR 000030007). (Source: Cancer Chemotherapy and Pharmacology)
Source: Cancer Chemotherapy and Pharmacology - October 24, 2020 Category: Cancer & Oncology Source Type: research